CANCER UPDATE PROVES POSITIVE
As always, cancer continues to hit the headlines but, fortunately, the headlines are becoming increasingly positive in terms of the progress that is being made in the battle against this terrible disease…
T
he University of Glasgow is just one of the sites that will participate in a new, multi- drug precision medicine trial for people
with rare cancers, which has been launched by Cancer Research UK, The University of Manchester and Roche Products Ltd (Roche).
The trial has been set up to recruit both paediatric and adult patients - with any rare cancer type - and is one of very few precision medicine platform trials in the world targeting these populations.
The DETERMINE trial aims to find out whether existing drugs, including those which are licensed for more common types of cancer, could also benefit patients with rare cancer types for which the drug currently isn’t licensed.
Worldwide, rare cancers make up 22 per cent of the cancers that are diagnosed each year, which is more than any single type of cancer.
Despite their prevalence, however, fewer treatment options exist for patients with rare cancers.
Patients eligible for the trial will have undergone genetic screening and found that they have one of the particular genetic mutations in their cancer that can be targeted by a drug on the trial.
Its unique design means that any treatment which appears to be working for patients on the trial will be submitted for review by the Cancer Drug Fund (CDF), which will then decide whether to collect more data and assess if the drug could be used as a routine treatment option on the NHS for patients with this cancer type.
Cancer Research UK’s Centre for Drug Development is sponsoring and managing the trial, with the University of Manchester leading it. Roche is providing seven of their targeted drugs to be evaluated in the first instance
While the first trial site has opened at the Christie NHS Foundation Trust, more sites are to follow, including the University of Glasgow, the Royal Marsden NHS Foundation Trust and the University of Birmingham, as well as sites across the entire adult and paediatric Experimental Cancer Medicine Centres (ECMC) network.
‘This platform trial,’ says Iain Foulkes, Executive Director of Research and Innovation at Cancer
34
scottishpharmacist.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
